The application relates to the field of pharmaceutical
chemistry. The application relates to a
hydrate crystal form of lazertinib monomethanesulfonate and a preparation method and application thereof. The
hydrate crystal form of lazertinib monomethanesulfonate provided by the application has at least one of the following advantages: good stability, good
solubility, good
dissolution, low hygroscopicity, uniform
particle size distribution, good morphology, good fluidity, good
crystallinity,
stable storage, avoidance of degradation,
impurity increase, appearance change and
crystal transformation during development and storage, simple and reliable preparation method, and great development value.